We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
Read MoreHide Full Article
Gilead Sciences Inc.’s (GILD - Free Report) company, Kite, announced that its Marketing Authorization Application (MAA) for KTE-X19 has been fully validated.Itis now under evaluation with the European Medicines Agency (EMA). KTE-X19 is an investigational chimeric antigen receptor (CAR) T cell therapy being developed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). MCL is a rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the "mantle zone" of the lymph node.
The MAA is supported by data from the single-arm, open-label, phase II ZUMA-2 study, which demonstrated an overall response rate of 93%, including 67% with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19 (median follow-up of 12.3 months).
Shares of the company have decreased 7.5% in the past year compared with the industry’s decline of 5.6%.
Kite submitted a biologics license application (BLA) for KTE-X19 to the FDA on Dec 11, 2019, for the treatment of adult patients with relapsed or refractory MCL. The candidate has been granted Breakthrough Therapy Designation (BTD) by the FDA and Priority Medicines (PRIME) by the EMA.
Apart from MCL, KTE-X19 is currently in phase I/II studies in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Gilead has a robust pipeline, with several development programs currently underway, ranging from phase I through phase III.
BioDelivery’s loss per share estimates have narrowed from 21 cents to 16 cents for 2019 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters by 159.38%, on average.
Guardant’s loss per share estimates have narrowed from $1.27 to 88 cents for 2019 and from $1.29 to $1.18 for 2020 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters by 39.21%, on average.
Denali’s loss per share estimates have narrowed from $2.04 to $2.02 for 2019 and from $2.40 to $2.39 for 2020 in the past 90 days.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
Gilead Sciences Inc.’s (GILD - Free Report) company, Kite, announced that its Marketing Authorization Application (MAA) for KTE-X19 has been fully validated.Itis now under evaluation with the European Medicines Agency (EMA). KTE-X19 is an investigational chimeric antigen receptor (CAR) T cell therapy being developed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). MCL is a rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the "mantle zone" of the lymph node.
The MAA is supported by data from the single-arm, open-label, phase II ZUMA-2 study, which demonstrated an overall response rate of 93%, including 67% with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19 (median follow-up of 12.3 months).
Shares of the company have decreased 7.5% in the past year compared with the industry’s decline of 5.6%.
Kite submitted a biologics license application (BLA) for KTE-X19 to the FDA on Dec 11, 2019, for the treatment of adult patients with relapsed or refractory MCL. The candidate has been granted Breakthrough Therapy Designation (BTD) by the FDA and Priority Medicines (PRIME) by the EMA.
Apart from MCL, KTE-X19 is currently in phase I/II studies in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Gilead has a robust pipeline, with several development programs currently underway, ranging from phase I through phase III.
Gilead Sciences, Inc. Price
Gilead Sciences, Inc. price | Gilead Sciences, Inc. Quote
Zacks Rank & Stocks to Consider
Gilead is currently a Zacks Rank #3 (Hold) stock.
A few better-ranked stocks in the biotech sector are BioDelivery Sciences International Inc. , Guardant Health Inc. (GH - Free Report) and Denali Therapeutics Inc. (DNLI - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioDelivery’s loss per share estimates have narrowed from 21 cents to 16 cents for 2019 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters by 159.38%, on average.
Guardant’s loss per share estimates have narrowed from $1.27 to 88 cents for 2019 and from $1.29 to $1.18 for 2020 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters by 39.21%, on average.
Denali’s loss per share estimates have narrowed from $2.04 to $2.02 for 2019 and from $2.40 to $2.39 for 2020 in the past 90 days.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>